Anemia in HIV-infected patients receiving highly active antiretroviral therapy

Journal of Acquired Immune Deficiency Syndromes

Volumn 29, Issue 1, 2002, Pages 54-57

  Moore, Richard D ^a   Forney, Darrell ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anemia; Antiretroviral therapy; Fatigue; Hemoglobin; Quality of life

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; HEMOGLOBIN; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA; ZIDOVUDINE;

ANEMIA; ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEMOGLOBIN DETERMINATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; REMISSION;

EID: 0036151430     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-200201010-00007     Document Type: Article

References (9)

1. Pathogenesis of anemia during human immunodeficiency virus infection
2. The blood in systemic disorders
3. Epidemiology of anemia in human immunodeficiency virus (HIV)-infected persons: Results from the multistate adult and adolescent spectrum of HIV disease surveillance project
4. Anemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe
5. Recombinant human erythropoietin in the treatment of anemia associated with human immunodeficiency virus (HIV) infection and zidovudine therapy
6. Improvement of anemia among HIV-infection injection drug users receiving highly active antiretroviral therapy
7. Understanding the clinical and economic outcomes of HIV therapy: The Johns Hopkins HIV Clinical Practice Cohort
8. Anemia and survival in HIV infection
9. Inadequate erythropoietin response to anemia in HIV patients: Relationship to serum levels of tumor necrosis factor-alpha, interleukin-6 and their soluble receptors